JPWO2021180952A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021180952A5
JPWO2021180952A5 JP2022554784A JP2022554784A JPWO2021180952A5 JP WO2021180952 A5 JPWO2021180952 A5 JP WO2021180952A5 JP 2022554784 A JP2022554784 A JP 2022554784A JP 2022554784 A JP2022554784 A JP 2022554784A JP WO2021180952 A5 JPWO2021180952 A5 JP WO2021180952A5
Authority
JP
Japan
Prior art keywords
amino
dihydro
propan
pyrimidin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554784A
Other languages
English (en)
Japanese (ja)
Other versions
JP7793529B2 (ja
JP2023517680A (ja
JP2023517680A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/056393 external-priority patent/WO2021180952A1/en
Publication of JP2023517680A publication Critical patent/JP2023517680A/ja
Publication of JPWO2021180952A5 publication Critical patent/JPWO2021180952A5/ja
Publication of JP2023517680A5 publication Critical patent/JP2023517680A5/ja
Priority to JP2025151939A priority Critical patent/JP2025186368A/ja
Application granted granted Critical
Publication of JP7793529B2 publication Critical patent/JP7793529B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554784A 2020-03-13 2021-03-12 Kcc2調節剤としての縮合ピリミジン化合物 Active JP7793529B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025151939A JP2025186368A (ja) 2020-03-13 2025-09-12 Kcc2調節剤としての縮合ピリミジン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989104P 2020-03-13 2020-03-13
US62/989,104 2020-03-13
PCT/EP2021/056393 WO2021180952A1 (en) 2020-03-13 2021-03-12 Fused pyrimidine compounds as kcc2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025151939A Division JP2025186368A (ja) 2020-03-13 2025-09-12 Kcc2調節剤としての縮合ピリミジン化合物

Publications (4)

Publication Number Publication Date
JP2023517680A JP2023517680A (ja) 2023-04-26
JPWO2021180952A5 true JPWO2021180952A5 (https=) 2024-03-21
JP2023517680A5 JP2023517680A5 (https=) 2024-03-21
JP7793529B2 JP7793529B2 (ja) 2026-01-05

Family

ID=74874882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554784A Active JP7793529B2 (ja) 2020-03-13 2021-03-12 Kcc2調節剤としての縮合ピリミジン化合物
JP2025151939A Pending JP2025186368A (ja) 2020-03-13 2025-09-12 Kcc2調節剤としての縮合ピリミジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151939A Pending JP2025186368A (ja) 2020-03-13 2025-09-12 Kcc2調節剤としての縮合ピリミジン化合物

Country Status (25)

Country Link
US (1) US20230151013A1 (https=)
EP (1) EP4103566B1 (https=)
JP (2) JP7793529B2 (https=)
KR (1) KR20220152319A (https=)
CN (4) CN119735594A (https=)
AU (1) AU2021234134B2 (https=)
BR (1) BR112022018173A2 (https=)
CA (1) CA3171192A1 (https=)
CL (1) CL2022002386A1 (https=)
CO (1) CO2022012884A2 (https=)
DK (1) DK4103566T3 (https=)
ES (1) ES2962136T3 (https=)
FI (1) FI4103566T3 (https=)
HR (1) HRP20231314T1 (https=)
HU (1) HUE064037T2 (https=)
IL (1) IL296265B2 (https=)
LT (1) LT4103566T (https=)
MX (1) MX2022011354A (https=)
PE (1) PE20230106A1 (https=)
PL (1) PL4103566T3 (https=)
PT (1) PT4103566T (https=)
RS (1) RS64823B1 (https=)
SI (1) SI4103566T1 (https=)
SM (1) SMT202300384T1 (https=)
WO (1) WO2021180952A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240132285A (ko) * 2021-12-08 2024-09-03 키네타, 인크. 비시클릭 헤테로아렌 및 그의 사용 방법
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
CN121548571A (zh) * 2023-04-05 2026-02-17 艾索尼斯治疗公司 Kcc2增强剂及其用途
WO2025188976A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neurodegenerative disorders
WO2025188977A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of addiction and insomnia
US20260048062A1 (en) * 2024-03-06 2026-02-19 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders
WO2025188974A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics
WO2025188951A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of seizure disorders
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes
WO2025188953A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease
US20250281498A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018217766A1 (en) * 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
EP3675861A4 (en) * 2017-09-01 2021-01-06 Kadmon Corporation, LLC ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
KR20210050493A (ko) * 2018-05-25 2021-05-07 더 칠드런스 메디칼 센터 코포레이션 척수 손상의 치료 방법

Similar Documents

Publication Publication Date Title
JP2025186368A5 (https=)
HRP20231314T1 (hr) Stopljeni pirimidinski spojevi kao modulatori kcc2
JP7737455B2 (ja) Sos1阻害剤としての新規キナゾリン誘導体化合物及びその用途{novel quinazoline derivatives as sos1 inhibitors and use thereof}
JP6754864B2 (ja) Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
US11028093B2 (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
JPWO2021180952A5 (https=)
KR101917972B1 (ko) ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체
RU2009125916A (ru) Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
ES2817902T3 (es) N-acil-N'-(piridin-2-il) ureas y análogos que presentan actividades anticancerosas y antiproliferativas
JP2010512337A5 (https=)
JP2010523668A5 (https=)
AU2013234009A1 (en) Heterocyclyl compounds as MEK inhibitors
WO2022170043A1 (en) Quinazoline derived compounds as egfr inhibitors and their uses thereof
ES2807785T3 (es) Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
JP2010510319A5 (https=)
JP2010512338A5 (https=)
KR20160116033A (ko) 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물
KR20090004976A (ko) 아졸카르복사미드 유도체
JP2019535689A5 (https=)
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
JP7462951B2 (ja) Jak阻害剤
JP2022502362A5 (https=)
JP2017523223A5 (https=)
ES2837765T3 (es) Pirido[3,4-b]indoles sustituidos para el tratamiento de trastornos del cartílago
CA2803055A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors